Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines

  • Rim, Chai Hong (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Seong, Jinsil (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • Received : 2016.09.07
  • Accepted : 2016.09.20
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

In oncologic practice, treatment guidelines provide appropriate treatment strategies based on evidence. Currently, many guidelines are used, including those of the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL-EORTC), National Comprehensive Cancer Network (NCCN), Asia-Pacific Primary Liver Cancer Expert (APPLE), and Korean Liver Cancer Study Group and National Cancer Centre (KLCSG-NCC). Although radiotherapy is commonly used in clinical practice, some guidelines do not accept it as a standard treatment modality. In this review, we will investigate the clinical practice guidelines currently used, and discuss the application of radiotherapy.

Keywords

References

  1. Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-94. https://doi.org/10.1016/j.radonc.2008.11.002
  2. Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int 2016 Jun 18 [Epub]. http://dx.doi.org/10.1111/liv.13191.
  3. Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2015;114:289-95. https://doi.org/10.1016/j.radonc.2014.11.033
  4. National Cancer Institute. Levels of evidence for adult and pediatric cancer treatment studies (PDQ) [Internet]. Bethesda, MD: National Cancer Institute; c2015 [cited 2016 Aug 17]. Available from: https://www.cancer.gov/publications/pdq/levels-evidence/treatment.
  5. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25. https://doi.org/10.1016/j.jclinepi.2012.03.013
  6. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-51. https://doi.org/10.1136/bmj.39493.646875.AE
  7. National Comprehensive Cancer Network. NCCN categories of evidence and consensus. [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016 [cited 2016 Aug 17]. Available from: https://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp.
  8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38. https://doi.org/10.1055/s-2007-1007122
  9. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16. https://doi.org/10.1002/hep.20636
  10. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004;40:124-31.
  11. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. https://doi.org/10.1371/journal.pone.0090929
  12. Hsu C, Chen BB, Chen CH, et al. Consensus development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2015;4:96-105. https://doi.org/10.1159/000367732
  13. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2. https://doi.org/10.1002/hep.24199
  14. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43. https://doi.org/10.1016/j.jhep.2011.12.001
  15. Huo TI, Huang YH, Lee SD, Wu JC. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348.
  16. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18:2210-8. https://doi.org/10.1200/JCO.2000.18.11.2210
  17. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329-36. https://doi.org/10.1016/S0360-3016(02)03929-9
  18. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-7. https://doi.org/10.1016/j.ijrobp.2014.01.017
  19. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003. https://doi.org/10.1002/cncr.23684
  20. Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-11. https://doi.org/10.1016/j.ijrobp.2011.03.019
  21. Kim SW, Oh D, Park HC, et al. Transcatheter arterial chemoembolization and radiation therapy for treatment-naive patients with locally advanced hepatocellular carcinoma. Radiat Oncol J 2014;32:14-22. https://doi.org/10.3857/roj.2014.32.1.14
  22. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  23. National Comprehensive Cancer Network [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016 [cited 2016 Aug 17]. Available from: https://www.nccn.org.
  24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, hepatobiliary cancers 2015. Fort Washington, PA: National Comprehensive Cancer Network; c2016.
  25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, hepatobiliary cancers 2016. 2 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016 [cited 2016 Aug 17]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  26. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7. https://doi.org/10.1148/radiol.2343040350
  27. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-9. https://doi.org/10.1053/jhep.2001.24233
  28. Pillai K, Akhter J, Chua TC, et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore) 2015;94:e580. https://doi.org/10.1097/MD.0000000000000580
  29. Head HW, Dodd GD 3rd, Dalrymple NC, et al. Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm: frequency of diaphragmatic injury. Radiology 2007;243:877-84. https://doi.org/10.1148/radiol.2433060157
  30. Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014;20:3100-11. https://doi.org/10.3748/wjg.v20.i12.3100
  31. Park HC, Yu JI, Cheng JC, et al. Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer 2016;5:162-74. https://doi.org/10.1159/000367766
  32. Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with threedimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-31. https://doi.org/10.1016/j.ijrobp.2006.08.015
  33. Cheng JC, Wu JK, Huang CM, et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003;56:229-34. https://doi.org/10.1016/S0360-3016(03)00091-9
  34. Hamacher HW, Kufer KH. Inverse radiation therapy planning: a multiple objective optimization approach. Discrete Appl Math 2002;118:145-61. https://doi.org/10.1016/S0166-218X(01)00261-X
  35. ClinicalTrials.gov [Internet]. Bethesda, MD: ClinicalTrials. gov; c2016 [cited 2016 Aug 17]. Available from: https://clinicaltrials.gov/.
  36. DeLaney TF. Proton therapy in the clinic. Front Radiat Ther Oncol 2011;43:465-85.
  37. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127(5 Suppl 1):S189-93. https://doi.org/10.1053/j.gastro.2004.09.033
  38. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009;115:5499-506. https://doi.org/10.1002/cncr.24619
  39. Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006;182:713-20. https://doi.org/10.1007/s00066-006-1564-2
  40. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015;16:465-522. https://doi.org/10.3348/kjr.2015.16.3.465
  41. Union for International Cancer Control (UICC). UICC staging system [Internet]. Geneva: Union for International Cancer Control (UICC); c2016 [cited 2016 Aug 17]. Available from: http://www.uicc.org.
  42. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-63. https://doi.org/10.1002/cncr.21811
  43. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-8. https://doi.org/10.1016/j.ijrobp.2005.01.002
  44. Pan CC, Kavanagh BD, Dawson LA, et al. Radiationassociated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-100. https://doi.org/10.1016/j.ijrobp.2009.06.092
  45. Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009;91:307-13. https://doi.org/10.1007/s11060-008-9713-3
  46. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009;115:2710-20. https://doi.org/10.1002/cncr.24300
  47. Jiang W, Zeng ZC, Zhang JY, Fan J, Zeng MS, Zhou J. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis 2012;29:197-205. https://doi.org/10.1007/s10585-011-9442-4
  48. Yoon SM, Kim JH, Choi EK, et al. Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis. Cancer Res Treat 2004;36:79-84. https://doi.org/10.4143/crt.2004.36.1.79
  49. Huang JF, Wang LY, Lin ZY, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:190-5. https://doi.org/10.1046/j.1440-1746.2002.02677.x

Cited by

  1. Bridging to liver transplantation in HCC patients vol.402, pp.6, 2016, https://doi.org/10.1007/s00423-017-1609-2
  2. Development of a deep neural network derived from contours defined by consensus-based guidelines for automatic target segmentation in hepatocellular carcinoma radiotherapy: A study protocol vol.6, pp.None, 2016, https://doi.org/10.12688/f1000research.12892.1
  3. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results vol.8, pp.35, 2017, https://doi.org/10.18632/oncotarget.19219
  4. Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutio vol.8, pp.55, 2017, https://doi.org/10.18632/oncotarget.21775
  5. γ-irradiation from radiotherapy improves the virulence potential of Candida tropicalis vol.12, pp.16, 2016, https://doi.org/10.2217/fmb-2017-0137
  6. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma vol.9, pp.3, 2016, https://doi.org/10.18632/oncotarget.23428
  7. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials vol.11, pp.None, 2016, https://doi.org/10.2147/ott.s164651
  8. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies vol.10, pp.None, 2016, https://doi.org/10.2147/cmar.s175703
  9. MicroRNA-146a-5p attenuates irradiation-induced and LPS-induced hepatic stellate cell activation and hepatocyte apoptosis through inhibition of TLR4 pathway vol.9, pp.2, 2016, https://doi.org/10.1038/s41419-017-0038-z
  10. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review vol.5, pp.2, 2018, https://doi.org/10.2217/hep-2018-0001
  11. The Clinical Utilization of Radiation Therapy in Korea between 2011 and 2015 vol.50, pp.2, 2016, https://doi.org/10.4143/crt.2017.096
  12. Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe vol.22, pp.3, 2016, https://doi.org/10.14701/ahbps.2018.22.3.274
  13. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review vol.129, pp.1, 2018, https://doi.org/10.1016/j.radonc.2018.02.030
  14. Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer vol.194, pp.11, 2018, https://doi.org/10.1007/s00066-018-1342-y
  15. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration vol.8, pp.None, 2016, https://doi.org/10.1038/s41598-018-34676-1
  16. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma vol.18, pp.None, 2016, https://doi.org/10.1186/s12885-018-4340-7
  17. Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma vol.18, pp.None, 2016, https://doi.org/10.1186/s12885-018-4953-x
  18. Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea vol.11, pp.None, 2016, https://doi.org/10.2147/cmar.s193761
  19. Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion vol.9, pp.None, 2016, https://doi.org/10.3389/fonc.2019.01065
  20. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? vol.11, pp.2, 2019, https://doi.org/10.3390/cancers11020230
  21. Dose verification for liver target volumes undergoing respiratory motion vol.42, pp.2, 2016, https://doi.org/10.1007/s13246-019-00737-6
  22. Radioprotective effects of mistletoe extract in zebrafish embryos in vivo vol.95, pp.8, 2016, https://doi.org/10.1080/09553002.2019.1590661
  23. Long-term Disease-free Survival after Trimodality Treatment of Recurrent Hepatocellular Carcinoma Involving the Inferior Vena Cava and Right Atrium vol.19, pp.2, 2019, https://doi.org/10.17998/jlc.19.2.149
  24. Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05) vol.51, pp.4, 2016, https://doi.org/10.4143/crt.2018.687
  25. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization vol.105, pp.5, 2016, https://doi.org/10.1016/j.ijrobp.2019.09.006
  26. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome vol.58, pp.12, 2016, https://doi.org/10.1080/0284186x.2019.1657942
  27. Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma vol.19, pp.None, 2020, https://doi.org/10.1177/1533033820937002
  28. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion vol.7, pp.None, 2016, https://doi.org/10.2147/jhc.s276528
  29. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints vol.26, pp.4, 2020, https://doi.org/10.3748/wjg.v26.i4.393
  30. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial vol.107, pp.1, 2016, https://doi.org/10.1016/j.ijrobp.2020.01.027
  31. Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy vol.20, pp.2, 2016, https://doi.org/10.17998/jlc.20.2.167
  32. lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity vol.11, pp.None, 2016, https://doi.org/10.3389/fonc.2021.572585
  33. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review vol.13, pp.8, 2016, https://doi.org/10.4240/wjgs.v13.i8.796
  34. De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference vol.106, pp.1, 2022, https://doi.org/10.1097/tp.0000000000003998
  35. Green synthesis of novel antifungal 1,2,4‐triazoles effective against γ‐irradiated Candida parapsilosis vol.355, pp.1, 2016, https://doi.org/10.1002/ardp.202100287